COX2 is well known to enhance malignant potential of urothelial carcinoma cells[9,10], and several types of COX2 inhibitors are clinically used for not only treatment but also prevention of bladder cancer[11]. This evidence concerns the gene PTGS2 and urinary bladder carcinoma.